United Therapeutics gains FDA approval for Tyvaso

07/30/2009 | American City Business Journals

The FDA cleared United Therapeutics' Tyvaso, an inhaled formulation of its injectable drug Remodulin, for pulmonary arterial hypertension. The approval comes with recommendations to make the product more patient-friendly by Oct. 31, 2010, and to test the drug for possible risks of oropharyngeal and pulmonary toxicities in patients by Dec. 15, 2013.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations